Savara Inc (NASDAQ:SVRA - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Savara in a report released on Friday, March 28th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.
Several other brokerages also recently issued reports on SVRA. Wells Fargo & Company began coverage on shares of Savara in a research report on Friday, December 20th. They issued an "overweight" rating and a $8.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.
Check Out Our Latest Stock Analysis on Savara
Savara Stock Down 3.7 %
Shares of NASDAQ:SVRA traded down $0.11 during mid-day trading on Monday, hitting $2.90. 906,979 shares of the company traded hands, compared to its average volume of 1,325,646. The firm's 50 day simple moving average is $2.73 and its 200 day simple moving average is $3.22. The firm has a market cap of $500.64 million, a P/E ratio of -6.74 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a 52-week low of $2.26 and a 52-week high of $5.34.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter.
Institutional Trading of Savara
Several institutional investors and hedge funds have recently bought and sold shares of SVRA. The Manufacturers Life Insurance Company increased its holdings in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock valued at $191,000 after acquiring an additional 3,706 shares during the last quarter. Altium Capital Management LLC increased its stake in Savara by 0.3% during the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock valued at $4,848,000 after purchasing an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after purchasing an additional 4,732 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Savara by 13.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock worth $135,000 after purchasing an additional 5,236 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after buying an additional 5,450 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Articles
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
